Skip to content

Lineage Cell Therapeutics, Inc.: 10-K filed 2012-03-14

What Lineage Cell Therapeutics, Inc. reported in its annual report filed 2012-03-14 (fiscal FY 2011): 32 published measures, 85 facts as tagged in accession 0001140361-12-015539.

This filing

Form
10-K (annual report)
Filed
2012-03-14
Fiscal period
fiscal FY 2011
Accession
0001140361-12-015539 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lineage Cell Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-3145,829,695USD
At 2010-12-3153,272,659USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-3128,646,001USD
At 2010-12-3138,172,229USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-3122,211,897USD
At 2010-12-3133,324,924USD
At 2009-12-3112,189,081USD
At 2008-12-3112,279USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-16,515,500USD365
2010-01-01 to 2010-12-31-11,184,618USD365
2009-01-01 to 2009-12-31-5,144,499USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-13,593,916USD365
2010-01-01 to 2010-12-31-7,732,884USD365
2009-01-01 to 2009-12-31-4,259,938USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-31960,281USD365
2010-01-01 to 2010-12-31220,771USD365
2009-01-01 to 2009-12-3161,276USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-313,862,414USD365
2010-01-01 to 2010-12-3125,767,456USD365
2009-01-01 to 2009-12-3116,482,966USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-1,202,713USD365
2010-01-01 to 2010-12-313,197,419USD365
2009-01-01 to 2009-12-31-46,226USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-12-31-80,470,009USD
At 2010-12-31-63,954,509USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-311,347,779USD
At 2010-12-31710,766USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,217,522USD365
2010-01-01 to 2010-12-31638,709USD365
2009-01-01 to 2009-12-31260,840USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-18,686,431USD365
2010-01-01 to 2010-12-31-9,852,133USD365
2009-01-01 to 2009-12-31-3,520,266USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-3124,955,374USD
At 2010-12-3135,572,678USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-313,146,655USD
At 2010-12-312,479,957USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-3123,041,193USD365
2010-01-01 to 2010-12-3113,532,433USD365
2009-01-01 to 2009-12-315,445,434USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2011-12-3151,174USD
At 2010-12-3145,470USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-13,699,691USD365
2010-01-01 to 2010-12-31-8,191,314USD365
2009-01-01 to 2009-12-31-3,181,729USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3149,035,788shares
At 2010-12-3147,777,701shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-12-3193,972USD
At 2010-12-3193,972USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-12-31-122,749USD
At 2010-12-31897,338USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2011-12-3141,458,181USD
At 2010-12-3149,425,657USD
At 2009-12-3111,046,989USD
At 2008-12-31-4,346,814USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2011-12-3118,619,516USD
At 2010-12-3115,386,905USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-31258,620USD
At 2010-12-31318,288USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-12-312,692,303USD
At 2010-12-312,202,284USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-18,443,883USD365
2010-01-01 to 2010-12-31-12,187,207USD365
2009-01-01 to 2009-12-31-5,143,909USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-9,341,502USD365
2010-01-01 to 2010-12-31-5,341,119USD365
2009-01-01 to 2009-12-31-2,263,705USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-01-01 to 2011-12-31373,349USD365
2010-01-01 to 2010-12-31138,659USD365
2009-01-01 to 2009-12-3134,591USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,991,200USD365
2010-01-01 to 2010-12-31790,117USD365
2009-01-01 to 2009-12-310USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2011-01-01 to 2011-12-31242,548USD365
2010-01-01 to 2010-12-31-2,335,074USD365
2009-01-01 to 2009-12-31-1,623,643USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-12-310USD365
2010-01-01 to 2010-12-310USD365
2009-01-01 to 2009-12-318,000,000USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31120,678USD365
2010-01-01 to 2010-12-3177,907USD365
2009-01-01 to 2009-12-31349USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-31,094USD365
2010-01-01 to 2010-12-3111,094USD365
2009-01-01 to 2009-12-3138,384USD365

Inspect the source

Entity
Lineage Cell Therapeutics, Inc. / CIK 0000876343
Captured
2026-09-20T05:01:04.503Z
SEC response SHA-256
de850ac42665e48058d541d948514740e0c9007b61646401dcae831c504c80bf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000876343.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))